Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns

Seeking AlphaSep 25 18:08 ET

Express News | Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older

BenzingaSep 25 15:52 ET

CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Have Endured a 59% Loss From Investing in the Stock Three Years Ago

Yahoo FinanceSep 22 08:52 ET

Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?

Yahoo FinanceSep 19 04:33 ET

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

Yahoo FinanceSep 18 18:00 ET

Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com

BusinesswireSep 16 10:10 ET